Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satipharm CBD capsules for mild sleep disturbance
ACTRN12622000464763Phase 3Completed
- Sponsor
- Cann Group Limited
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Satipharm CBD and Placebo-COD Research Private Ltd in sleep disorder and Insomnia (4 arms), sponsored by Cann Group Limited. Primary endpoints: Change in Insomnia Severity Index score and Change in PROMIS Sleep Disturbance score. Started Mar 2022; status: completed.
02
Drugs
Satipharm CBDPlacebo-COD Research Private Ltd
03
Conditions
sleep disorderInsomnia
Beyond the preview
Go deeper on ACTRN12622000464763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000464763.